Monday's Most Compelling Trades
Last week, D-Wave Quantum (QBTS) gained 48.1%. The quantum computing firm lost $0.02 a share. Revenue, however, quintupled (+507.3% Y/Y to $15 million.D-Wave’s CEO, Dr. Alan Baratz, said that the company recognized revenue from its Advantage system sale to a research institution. The sale demonstrates that demand for quantum computing may grow over classical computing.Viatris (VTRS) continued trending higher in the last few weeks. In the first quarter, it earned $0.50 per share (non-GAAP). Revenue fell by 11.2% Y/Y to $3.25 billion. Viatris said that over half of its U.S. revenue comes from U.S.-based manufacturing. That would mitigate the impact of tariffs on its sales.In the chip sector, Arm Holdings (ARM) pulled back after issuing a weak forecast. In Q4, Arm posted revenue of $1.24 billion, up by 33.6% Y/Y. While the stock is overvalued, Arm has growth catalysts in the automotive and hyperscaler markets. Customers need silicon customization to achieve higher performance. By investing in the software and hardware platform, Arm will develop a long-term relationship with its partners.ARM stock has strong buying interest in the $115 price range. It traded in a range of $80.00 to $188.75 in the last 52-week period. Investors cautious about ARM’s valuation may consider Texas Instruments (TXN), Micron Technology (MU), Nvidia (NVDA), or Taiwan Semiconductor (TSM)
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


